True or False: The Centers for Medicare and Medicaid Services announced that insurance plans may use copay accumulator and maximizer programs in 2023.

The statement is true because, in 2023, the Centers for Medicare and Medicaid Services (CMS) did permit insurance plans to implement copay accumulator and maximizer programs. These programs are designed to manage how patient assistance from drug manufacturers counts toward a patient's out-of-pocket costs. Under these programs, the funds provided by pharmaceutical companies to cover patients' copays do not contribute to the patient’s deductible or maximum out-of-pocket limit for the plan year.

CMS's decision reflects an understanding of the evolving landscape of healthcare financing, where such cost-sharing strategies are increasingly being used by insurance plans as a means of managing expenses. Thus, recognizing the allowance of these programs by CMS validates the response, emphasizing the importance for those in the healthcare and insurance sectors to be informed about such policies as they affect patient care and financial responsibilities.

Other options do not accurately capture the CMS's announcement. The option stating "Depends on the insurance policy" implies variability without acknowledging the blanket allowance by CMS for 2023, which misrepresents the directive. The response indicating that it is false only for specific medications fails to account for the overarching policy that permits these programs broadly, regardless of medication type.